"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
(Generic versions may still be available.)
(1% Sodium Hyaluronate)
PROVISC® (sodium hyaluronate) Viscoelastic Preparation is a sterile, non-pyrogenic, high molecular weight, noninflammatory highly purified fraction of sodium hyaluronate, dissolved in physiological sodium chloride phosphate buffer. Each mL of PROVISC contains active 10.0mg sodium hyaluronate; 0.56mg dibasic sodium phosphate, anhydrous; 0.04mg monobasic sodium phosphate; 8.4mg sodium chloride; hydrochloric acid and/or sodium hydroxide to adjust pH and water for injection.
Last reviewed on RxList: 2/15/2005
This monograph has been modified to include the generic and brand name in many instances.
Additional Provisc Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.